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Abstract
Objectives: We describe pregnant womens’ access to PMTCT and HAART services and associated birth outcomes in South
Africa.
Methods: Women recuperating in postnatal wards of a referral hospital participated in an evaluation during February–May
2010 during which their maternity records were examined to describe their access to VCT, CD4 Counts, dual ART or HAART
during pregnancy.
Results: Of the 1609 women who participated in this evaluation, 39% (95%CI36.7–41.5%) tested HIV-positive during their
pregnancy. Of the HIV-positive women 2.9% did not have a CD4 count done and an additional 31.3% did not receive their
CD4 results. The majority (96.8%) of the HIV-positive women commenced dual ART at their first antenatal visit independent
of their CD4 result. During February–May 2010, 48.0% of the women who had a CD4 result were eligible for HAART
(CD4,200 cells/mm
3) and 29.1% of these initiated HAART during pregnancy. Under the current South African PMTCT
guidelines 71.1% (95%CI66.4–75.4%) of HIV positive pregnant women could be eligible for HAART (CD4,350 cells/mm
3).
There were significantly more preterm births among HIV-positive women (p=0.01) and women who received HAART were
no more at risk of preterm deliveries (AOR 0.73;95%CI0.39–1.36;p=0.2) as compared to women who received dual ART. Nine
(2.4%; 95%CI1.1–4.5%) HIV exposed infants were confirmed HIV infected at birth. The in-utero transmission rate was highest
among women who required HAART but did not initiate treatment (8.5%) compared to 2.7% and 0.4% among women who
received HAART and women who were not eligible for HAART and received PMTCT prophylaxis respectively.
Conclusion: In this urban South African community the antenatal HIV prevalence remains high (39%) and timeous access to
CD4 results during pregnancy is limited. Under the current South African guidelines, and assuming that access to CD4
results has improved, more than 70% of HIV-positive pregnant women in this community would be requiring HAART.
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Introduction
South Africa, with an estimated 5.6 million people living with
HIV, has the largest burden of HIV disease globally [1]. Among
these, 330,000 are pediatric HIV infections and are largely due to
mother to child transmission. As at mid-2006, during a one year
period 38,000 infants were born HIV infected and 26,000 infants
in South Africa subsequently acquired HIV during breastfeeding
[2]. This was despite the availability of HIV counseling and
testing, antiretroviral prophylaxis (single dose NVP) and infant
feeding support to prevent mother to child transmission (PMTCT)
of HIV in the country.
Given the increasing evidence of the beneficial effects of more
than one antiretroviral drug for PMTCT, the National Depart-
ment of Health in South Africa in 2008 took a decision on
commissioning a dual antiretroviral regimen as the standard of
care for PMTCT for pregnant women with a CD4 count .200
cells/mm
3. In addition, pregnant women with a CD4 count ,200
cells/mm
3 were eligible for triple antiretroviral drugs as treatment
for themselves (HAART) [3]. The South African PMTCT policy
(2008) was introduced to all primary health care clinics in the
Umlazi area in February 2008. Women attending antenatal clinics
at the primary health centres received HIV counseling and testing.
If they tested positive for HIV, women were screened for eligibility
for HAART or AZT/NVP as PMTCT prophylaxis based on their
CD4 count. Women who were eligible for HAART (CD4,200
cells/mm
3) at the primary health care clinics were referred to
Prince Mshyeni Hospital to commence HAART. HAART was
not provided at primary health care clinics. Women with
CD4.200 cells/mm
3 should have received ZDV twice daily
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27907(300 mg) from 28 weeks of pregnancy. During labour women
should have received a 3 hourly dosing of AZT after taking a
single dose of NVP at the onset of labour. HIV exposed infants are
routinely tested for HIV from 6 weeks of age by DNA PCR
performed on dried blood spots.
There are isolated reports evaluating the implementation of
recent PMTCT policy changes ie. HAART for women who are
eligible and dual AZT/NVP prophylaxis for those who are not yet
eligible for HAART [4,5]. As opposed to the preceding South
African policy of using single dose NVP for PMTCT, it is expected
that the complexity of the recent regimens would require well
trained staff, well-co-ordinated services and intensive supervision.
Hence implementation of new policies should be evaluated in it’s
infancy to identify protocol deviations that could inevitably
become the standard of care if not corrected earlier, and highlight
operational challenges that lead to suboptimal coverage and
unfavourable outcomes. In May 2010, the South African PMTCT
guidelines changed once again to ensure the provision of triple
antiretroviral drugs as treatment (HAART) for all HIV positive
pregnant women with a CD4,350 cells/mm
3 [6].
We describe pregnant womens’ access to PMTCT and HAART
services at primary health care clinics in KwaZulu Natal prior to
the implementation of the PMTCT policy change in May 2010.
We also compare birth outcomes such as preterm delivery,
stillbirths, low birth weight and inutero HIV transmission and
neonatal morbidity in 3 categories of women viz. women who
received ART prophylaxis for PMTCT (HAART ineligible),
women eligible for HAART but did not commence HAART
(HAART eligible/untreated) and women who were eligible for
and commenced HAART (HAART eligible/treated).
Methods
This is a cross-sectional evaluation of PMTCT and HAART
services and birth outcomes in Umlazi, the second largest
township in South Africa with an estimated HIV antenatal
prevalence of 40%. The evaluation conducted postnatally
comprised of a maternity chart audit conducted in the post
delivery wards of Prince Mshiyeni Memorial Hospital during a
four month period between February and May 2010. Prince
Mshiyeni Hospital is a District/Regional Hospital, supports 17
primary health care clinics and has an annual birth rate of 12,000.
A written informed consent from all potential participants was
obtained prior to any research activity. The informed consent
(Zulu and English) were administered by two trained research
assistants. Maternity records of consenting study participants were
examined to describe their antenatal attendance, access to
voluntary counseling and testing and access to CD4 Counts,
AZT/NVP and HAART. Birth outcomes such as stillbirth rate,
Low birth weight rate, preterm delivery rate and inutero HIV
transmission rates were compared between the 3 categories of
women viz. HAART ineligible, HAART eligible/untreated and
HAART eligible/treated. A dried blood spot was collected from a
subsample of HIV exposed infants at birth for HIV diagnosis by
DNA PCR.
The following data were collected by chart review:
N Demographic and Antenatal Attendance to include Gestation-
al Age at Booking, Gravidity, Marital Status, Age and Number
of Antenatal Visits
N VCT, PMTCT and ARV access to include record of VCT
access, HIV test results, access to CD4 investigation, CD4
result, eligibility for HAART, access to HAART or PMTCT
ARV prophylaxis (AZT/NVP).
N Obstetric and Birth Outcomes to describe Birth Outcome
(LiveBirth/MSB/FSB), Gestational age at birth, and Birth
Weight.
Stata version 10 (StataCorp, Texas, U.S.A) was used to analyse
the data. A general descriptive analysis was conducted to address
all objectives using median, mean, range and 95%CI where
applicable. Maternal characteristics presented as categorical data
were compared using the Pearson’s chi square test. A multivariate
analysis was performed in determining independent associations
between birth outcomes, HIV status and exposure to HAART. A
p value of ,0.05 was considered statistically significant. Data were
analysed according to stratification of the study population with
CD4,200 cells/mm
3, CD4.200 cells/mm
3, HAART ineligible,
HAART eligible/untreated and HAART eligible/treated.
The study was approved by the Ethics Committee of the Nelson
R Mandela School of Medicine. All patient details remained
confidential and a written informed consent was obtained from
eligible participants.
Results
A total of 1622 women participated in this postnatal audit;
36.6% of the total deliveries at this regional hospital for the period
February to May 2010 (Figure 1). The maternity department of
the hospital recorded an average of 35 births a day and we
evaluated an average of 16 participants per day. According to their
antenatal records, the women who delivered at Prince Myshyeni
Hospital during the 4 month study period received antenatal care
at any one of the 37 primary health care (PHC) clinics in the
catchment area. The study sample therefore included a represen-
tation of all primary health care facilities in the Umlazi area.
One thousand, six hundred and nine (99.2%) women who
participated in the audit were tested for HIV at their respective
PHC clinics during their antenatal care; 630 (39%; 95%CI 36.7–
41.5) tested positive for HIV (Figure 1).
The median age (6SD) of this study population was 24 (66.1)
years; half the population were 24 years or younger (Table 1). One
in 3 women was pregnant for the first time (32%), and the majority
(68%) had 2 children or more including this recent birth. The
majority of women (88.8%) were single and not living with their
partner. Women registered for antenatal care at a median
gestational age of 23, ranging from 4 to 39 weeks (Table 1).
Two-thirds (74.3%) of the women registered between 14 and 28
weeks in pregnancy and 1.2% registered .36 weeks in gestation.
Demographic and antenatal registration characteristics did not
differ between the HIV positive and negative groups of women.
Among the 630 women with a positive HIV status, 97.3% had a
CD4 test performed. CD4 results were unavailable for 34.2% of
women (2.9% did not have a CD4 count done and 31.3% did not
receive their results (Figure 2). The median CD4 count for this
population was 285 (IQR 139–392) cells/mm
3. Among the
women who had a CD4 result 199 (48% 95%CI 43.1–52.9) were
eligible for HAART according to the 2008 PMTCT guidelines
(Figure 3). Six hundred and ten (96.8%) of the HIV positive
women initiated dual ART prophylaxis for PMTCT independent
of their CD4 result; and 58 (9.2%) of of all HIV positive pregnant
women initiated HAART. Among the women eligible for
HAART (CD4,200 cells/mm
3), 29.1% initiated HAART during
their pregnancy and 18 (2.9%) of HIV positive pregnant women
did not receive any antiretroviral drugs for PMTCT or treatment.
Among the women who had a CD4 result, 295 (71.1%; 95%CI
66.4–75.4) had a CD4,350 cells/mm
3 and would have been
eligible for HAART according to the current (2010) PMTCT
guidelines (Figure 3).
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(n=1622). The median gestational age at delivery in the preterm and
term groups were 35 (16.5–37) and 38 (38–40) weeks respectively.
There was a significantly higher proportion of preterm births among
the HIV positive women (25.20% vs 19.78%; p=0.01) (Table 2).
Women who received HAART were no more at risk of preterm
deliveries as compared to their counterparts who were eligible but did
not receive HAART (AOR 0.73; 95%CI 0.39–1.36; p=0.2) (Table 3).
Forty eight (3.0%) still births were reported for the study
population, and the stillbirth rate did not differ significantly
Figure 1. Study Population Included in the PMTCT/ART Service Evaluation. *PHC – Primary Health Care Clinics.
doi:10.1371/journal.pone.0027907.g001
Table 1. General Characteristics of Study Population n=1622.
N % Min Max Median(SD)
Age (years) 12 50 24(6.1)
24 or younger 852 52.5
25 or older 770 47.5
Marital Status
Single and Not Living with Partner 1441 88.8
Married 112 6.9
Single and Living with Partner 4 0.3
Other 65 4.0
Gravidity 1 11 2(1.1)
Single 519 32.0
Multiple 1,103 68.0
Gestational Age at Antenatal Registration 4 39 23(6.2)
,14 wk 115 7.1
14–28 wk 1196 74.3
29–36 wk 217 13.5
.36 wk 19 1.2
HIV Status
HIV+ 630 39.0%
CD4 count (cells/mm
3) 415 13 1228 285(IQR 139–392)
Birth Weight 1564 0.6 5.3 3.1(0.59)
LBW (,2500 g) 232 14.8%
Normal 1,331 85.2%
Birth Outcome
Live Birth 1,562 97.0%
Still Birth (MSB+FSB) 48 3.0%
doi:10.1371/journal.pone.0027907.t001
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vs 33.4/1000 births) (p=0.43) (Table 2). Maternal exposure to
HAART as treatment did not influence the still birth rate in this
population (AOR 0.23; 95%CI 0–1.4; p=0.11) (Table 3),
although macerated still births were more common among women
who were eligible for HAART and did not initiate HAART as
compared to their counterparts who initiated HAART (64/1000
births vs 17/1000 births). This association was not statistically
significant (p=0.28).
Excluding the preterm births, the mean (6 SD) birthweight of
children born was 3.160.59; 232 (14.8%) of the infants weighed
,2500 g at birth (LBW). LBW was significantly more common
among HIV positive women (p=0.002) (Table 2). Exposure to
HAART as treatment did not significantly influence birth weight
(AOR 1.03; 95%CI 0.4–2.0; p=0.53 (Table 3)).
Three hundred and 71 (58.9%) of the 630 HIV exposed infants
were tested for HIV by DNA PCR at birth; 9 of these infants were
confirmed HIV infected (2.4%; 95%CI 1.1–4.5) at birth. Eight of
the 9 (88.9%) infants were born to women with CD4 count
ranging between 13 and 41. None of these women initiated
HAART despite being eligible for treatment. The in-utero
transmission rate was highest among women who required
HAART but did not initiate treatment (8.5%) compared to
2.7% and 0.4% among women who received HAART and
women who were not eligible for HAART and received PMTCT
prophylaxis respectively.
Figure 2. Women’s Access to Dual ART regimen for PMTCT or HAART as treatment based on the availability of CD4 results and CD4
Count,200 (n=630).
doi:10.1371/journal.pone.0027907.g002
Figure 3. Using CD4 Count to guide clinical management of HIV positive pregnant women (n=630).
doi:10.1371/journal.pone.0027907.g003
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A year ago (2010) under the previous South African policy for
the management of HIV pregnant women with a CD4 count
,200 cells/mm
3, a third (34%) of HIV positive pregnant women
in a large urban community did not receive their CD4 results
during pregnancy and hence missed the opportunity of being
referred for HAART. Of greater concern, only 29% of the HIV
positive pregnant women who required HAART actually initiated
HAART during pregnancy. The impact of not receiving HAART
was seen in the 3 fold higher incidence of inutero HIV
transmission among women who were HIV positive, with a
CD4,200 cells/mm
3 and did not receive HAART.
Since South Africa revised their guidelines on the use of ARV
for PMTCT in 2010, a shift in the eligibility criteria of CD4,350
cells/mm
3 would translate to 71% of the current HIV positive
pregnant women in this South African study population being
eligible for HAART [6]. In a Zambian cohort of pregnant women,
54% of women had a CD4 count ,350 cells/mm
3 and a larger
proportion (68%) met the new WHO treatment criteria if clinical
stage III in addition to CD4 count ,350 cells/mm
3 were
considered [7,8]. The new guidelines WHO were based on
overwhelming evidence with an intent to improve the mother’s
health while ensuring optimal prevention of MTCT [7].
Commencing pregnant women with CD4,350 cells/mm
3 with
HAART could prevent more than 75% of MTCT not only during
pregnancy but through breastfeeding as well [9–11]. Our study
demonstrated a 3 fold higher in-utero transmission rate (8.5%)
among women who required HAART (CD4,200 cells/mm
3) and
did not receive this treatment as compared to those who were
eligible and received treatment. Historically, in utero transmission
accounted for 20–30% of vertical transmission of HIV in the
absence of an intervention [12]. In the PEPI study in Malawi, in
utero HIV transmission was reportedly 6.7% but higher (17.8%)
among women with incident HIV infections in pregnancy [13].
Yet another reason for HAART in all pregnant women who test
HIV positive independent of a CD4 count. The BAN study
conducted in Malawi reported a 4.9% in-utero transmission [11].
In the Kesho Bora study, lower in utero transmission was
significantly associated with undetectable maternal viral load at
delivery and in the presence of triple antiretroviral (2.5% vs 1.8%)
as opposed to ZDV and single dose NVP [10].
The latest recommendation underscores the use of HAART for
HIV positive pregnant women with CD4,350 cells/mm
3 based
on the overwhelming evidence of a strong association between
HIV and maternal deaths in resource limited countries with a high
HIV burden. Maternal mortality rate in South Africa for the
2005–2007 triennium was reported as 152 per 100,000 deliveries,
Table 2. Birth Outcomes among HIV positive and Negative women.
HIV Positive
N=630
HIV Negative
N=928 OR (95%CI) P value
Gestational Age at Delivery*
,37 weeks 158 (25.20%) 194 (19.78%)
.37 weeks 469 (37.3%) 787 (62.7%) 1.37 (1.08–1.74) 0.01
Birth Outcome
Stillbirths 17 (2.73%) 31 (3.17%)
Live Births 605 945 0.91 (0.5–1.6) 0.43
Birthweight
Median±SD 3.160.50 3.160.47
,2500 g 43 (9.4%) 42 (5.4%)
$2500 g 587 886 1.56 (1.18–2.07) 0.002
*Gestational Age at Birth was calculated using the Ballard Score.
doi:10.1371/journal.pone.0027907.t002
Table 3. Birth Outcomes among HIV positive women who received or did not receive PMTCT prophylaxis or HAART (eligibility
based on available CD4 count).
PMTCT Eligible and
Received PMTCT AZT/
NVP* (n-216)
HAART Eligible and
received HAART
(n=58)
HAART Eligible but did
not receive HAART
(n=141) Total N=415
Adjusted Odds
Ratio (95%CI) p value
Preterm 2 (1.6%) 34 (26.6%) 92 (71.9%) 128 (31.1%) 0.73 (0.4–1.4) 0.20
Term 212 24 48 284
Stillbirths 1 (9.0%) 1 (9.0%) 9 (81.8%) 11 (2.7%) 0.23 (0–1.4) 0.11
Live Births 213 57 131 401
Birthweight ,2500 g 3 (27%) 4 (36.4%) 4 (36.4%) 11 (2.7%) 1.03 (0.4–2.0) 0.53
Birthweight $2500 g 211 54 136 401
*Only 2 women did not receive PMTCT prophylaxis AZT/NVP. Excluded all other women who received PMTCT prophylaxis but their eligibility for HAART was unknown
(CD4 count unknown).
doi:10.1371/journal.pone.0027907.t003
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Pregnancy related sepsis remains the 4
th commonest cause of
maternal deaths and most likely related to HIV and an
immunocompromised state. According to this ‘‘Saving Mother’’
report, pregnant women who are HIV infected are 10 times more
likely to die in the pueperium period as compared to HIV
uninfected women (MMR 327.7/100,000 vs 34.4/100,000).
Increasing the CD4 threshold for HAART in South Africa was
therefore much needed to reduce HIV related maternal mortality.
Several major studies present conflicting evidence of a link
between preterm deliveries and exposure to HAART during
pregnancy [15,16]. Other studies have implicated the use of
protease inhibitors in increased risk of preterm births [17,18]. A
South African study reported a significantly higher premature
birth rate of 5% in HAART unexposed women vs 14% in
HAART exposed women [19]. The investigators concluded that
early HAART exposure was strongly associated with an increased
risk for preterm births. However, the study population only
comprised of immunocompromised women with a CD4 count
,250 cells/mm
3 [19]. Our conclusions are inconsistent with the
latter study. We demonstrated a higher proportion of preterm
births among women who required HAART (CD4,200 cells/
mm
3) independent of HAART exposure. There was no added
effect of HAART exposure, hence providing further evidence that
women who require HAART (severely immunocompromised) are
at a higher risk of preterm births as compared to their counterparts
with a CD4.200 cells/mm
3 (not yet immunocompromised).
Previous studies have not had an opportunity to compare the
occurrence of preterm births in women eligible for and did not
receive HAART as compared to their counterparts who received
HAART or women with CD4.200 cells/mm
3. In a pooled
analysis comparing highly active antiretroviral therapy with dual
regimens for PMTCT, Townsend et al reiterate an association
with preterm delivery and HAART but also propose that
conflicting reports of such an association between HAART and
preterm births could be due to confounding determinants,
variability in study design, population variability and differences
in data collected [20]. Our study adds to a list of previous studies
demonstrating no link between HAART and preterm births, and
further supports a stronger association between preterm birth and
advanced HIV disease stage independent of HAART.
Undoubtedly, there are concerns to offering HAART to 30%
women who may not yet require HAART that include side effects
such as anemia and hepatotoxicity. The safety of triple ART drug
regimens in pregnant women with CD4.350 and the effect of
discontinuing such regimens on maternal health remains to be
confirmed.
We also agree that there are major economical and logistical
challenges in expanding HIV treatment programmes in resource-
limited countries [2,21,22]. Our study highlights one of these
many challenges in receiving CD4 results timeously to commence
HAART early. A third of the study population who had a CD4
done during pregnancy, did not have a CD4 result at the time of
delivery. In such a setting with a high antenatal HIV prevalence
(39%), and more than two thirds (71%) of women eligible for
HAART with a CD4,350 cells/mm
3, it would be logical/prudent
to consider the ‘‘Test and Treat’’ principle to ensure all pregnant
women who are HIV infected receive HAART early in
pregnancy. Alternatively, in the absence of reliable access to
CD4 testing or the timeous availability of CD4 results, clinical
staging has been proposed as an alternative indication for
HAART. However, the sensitivity of clinical staging in identifying
patients in need for HAART has been reportedly low as compared
to CD4 results (23% vs 94%) in the multi-country MTCT-Plus
Initiative [23]. Given the overwhelming evidence of benefits of
initiating HAART early in pregnancy and the vast majority of
women eligible for HAART we are more inclined to support the
recommendations proposed by Zolfo et al for universal initiation
of HAART in all HIV positive pregnant women irrespective of
CD4 count [24].
As predicted, the growing case load of patients requiring
HAART over time has posed numerous challenges to central
facilities that provide HAART services in the public health sector.
In our study population, women were referred to a central
HAART service at a hospital, the only one that supported 17 such
PHC clinics in the area. Women who were referred for HAART
to the central service often returned to the PHC for continued
antenatal care without registering for HAART. The lack of human
resources at the centralised HAART services, distance between
PHC clinics and HAART services, poor referral mechanisms and
non-existent links between PHC and the central service are
plausible reasons for the vast majority of women not initiating
HAART in pregnancy. Based on the above arguments, countries
have been encouraged to decentralise HAART services to PHC
facilities to ensure wide scale coverage. Nursing personnel
currently providing and monitoring PMTCT prophylaxis in
pregnant women would require additional training in modifying
their management protocols to include HAART. A combination
of differential management protocols for women in the varying
stages of the disease and a lack of effective monitoring systems at a
PHC also pose a challenge to an already overburdened human
resource system.
There are several limitations to the study. Access to HIV clinical
services was based on a retrospective assessment of documentation in
medical records, and these sources of information could not be
verified. Information related to the nature and actual commencement
of the HAART regimens as well as other obstetric risk factors were
limited. This study was conducted in a single urban community and
may not be representative of the larger South African population.
In conclusion, if more than 70% of HIV positive pregnant
women in an urban South African community are requiring
HAART under the current South African guidelines, and access to
CD4 count remains limited, the country’s HIV management policy
for pregnant women needs to be modified. The high HIV antenatal
prevalence (39%), the majority (70%) of women being eligible for
HAART (CD4,350 cells/mm
3) and the small proportion of
women actually initiating HAART at a referral centre are all
compelling reasons for initiating HAART in all HIV positive
pregnant women at primary health clinics until after delivery or
until breastfeeding ceases and there is no further risk of MTCT.
Primary health clinics do not have laboratory services and may
often lack good communication links with regional laboratories,
hence the limited access to CD4 results would prevent the vast
majority of HIV positive pregnant women from receiving HAART.
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